Biotech Values

[dewophile]

thx - on quick glance looks like cirrhotics could benefit from 24 weeks with either regimen - with the exception of GT1b patients who had outstanding results with 12 week of the ABBV regiment (i didnt see a breakdown in cirrhotics by genotype in ION studues - but numbers probably too small anyway to draw conclusion)

re ION-3 there were an unusually large number of pts ost to follow up in the 12 week arm compared to 8 week arms. the VIROLOGIC failure rate in the 12 week arm was 1% versus 4-5% in the 8 week arm, which is a small but still meaningful difference. If i were a patiient i wouldn't want 8 weeks of GILD's regimen (and i question now if they get approved for 8 weeks)